Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients

Breast Cancer Research and Treatment

Volumn 149, Issue 3, 2015, Pages 767-779

  Li, Zibo ^a   Guo, Xinwu ^b   Wu, Yepeng ^a   Li, Shengyun ^a   Yan, Jinhua ^a   Peng, Limin ^b   Xiao, Zhi ^a   Wang, Shouman ^a   Deng, Zhongping ^b   Dai, Lizhong ^b   Yi, Wenjun ^a   Xia, Kun ^a   Tang, Lili ^a   Wang, Jun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Sanway Gene Technology Inc   (China)

Author keywords

Biomarker; Breast cancer; Candidate gene; Methylation; Microfluidic PCR; Next generation sequencing

Indexed keywords

BISULFITE; ESTROGEN RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ACADL GENE; ADAMTSL1 GENE; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CAV1 GENE; CHINESE; CONTROLLED STUDY; CST6 GENE; DBC1 GENE; DNA METHYLATION; EARLY DIAGNOSIS; EGFR GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENETIC CORRELATION; GENETIC MARKER; GREM1 GENE; GSTP1 GENE; HUMAN; HUMAN TISSUE; IGFBP3 GENE; MAJOR CLINICAL STUDY; MICROFLUIDIC ANALYSIS; NPY GENE; PDGFRB GENE; POLYMERASE CHAIN REACTION; PPM1E GENE; PREDICTIVE VALUE; PRIORITY JOURNAL; PTGS2 GENE; RUNX3 GENE; SFRP1 GENE; SFRP2 GENE; SOX17 GENE; TISSUE DISTRIBUTION; TNFRSF10D GENE; WRN GENE; AGED; BREAST NEOPLASMS; DIAGNOSTIC USE; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PROMOTER REGION;

ADULT; AGED; BREAST NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84925533283     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3276-8     Document Type: Article

References (36)

1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed on 17 Aug 2014
2. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L (2003) The case for early detection. Nat Rev Cancer 3(4):243–252. doi:10.1038/nrc1041
3. Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7(1):21–33. doi:10.1038/nrg1748
4. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683–692. doi:10.1016/j.cell.2007.01.029
5. Suijkerbuijk KP, van Diest PJ, van der Wall E (2011) Improving early breast cancer detection: focus on methylation. Ann Oncol 22(1):24–29. doi:10.1093/annonc/mdq305
6. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8(4):286–298. doi:10.1038/nrg2005
7. Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY (2011) Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 6(1):e16080. doi:10.1371/journal.pone.0016080
8. Fackler MJ, Bujanda ZL, Umbricht C, Teo WW, Cho S, Zhang Z, Visvanathan K, Jeter S, Argani P, Wang C, Lyman JP, de Brot M, Ingle JN, Boughey J, McGuire K, King TA, Carey LA, Cope L, Wolff AC, Sukumar S (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74(8):2160–2170. doi:10.1158/0008-5472.CAN-13-3392
9. Chan KC, Jiang P, Chan CW, Sun K, Wong J, Hui EP, Chan SL, Chan WC, Hui DS, Ng SS, Chan HL, Wong CS, Ma BB, Chan AT, Lai PB, Sun H, Chiu RW, Lo YM (2013) Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci USA 110(47):18761–18768. doi:10.1073/pnas.1313995110
10. Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knuchel R, Dahl E (2013) Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 15(1):R4. doi:10.1186/bcr3375
11. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y (2007) Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9(4):R57. doi:10.1186/bcr1762
12. Fiegl H, Millinger S, Goebel G, Muller-Holzner E, Marth C, Laird PW, Widschwendter M (2006) Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res 66(1):29–33. doi:10.1158/0008-5472.CAN-05-2508
13. Bediaga NG, Acha-Sagredo A, Guerra I, Viguri A, Albaina C, Ruiz Diaz I, Rezola R, Alberdi MJ, Dopazo J, Montaner D, Renobales M, Fernandez AF, Field JK, Fraga MF, Liloglou T, de Pancorbo MM (2010) DNA methylation epigenotypes in breast cancer molecular subtypes. Breast Cancer Res 12(5):R77. doi:10.1186/bcr2721
14. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12(3):R36. doi:10.1186/bcr2590
15. Ruike Y, Imanaka Y, Sato F, Shimizu K, Tsujimoto G (2010) Genome-wide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 11:137. doi:10.1186/1471-2164-11-137
16. Hill VK, Ricketts C, Bieche I, Vacher S, Gentle D, Lewis C, Maher ER, Latif F (2011) Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Res 71(8):2988–2999. doi:10.1158/0008-5472.CAN-10-4026
17. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, Marks J, Ethier S, Gray JW, Wolff AC, Cope LM, Sukumar S (2011) Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71(19):6195–6207. doi:10.1158/0008-5472.CAN-11-1630
18. Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412
19. Cornen S, Guille A, Adelaide J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A, Raynaud S, Charafe-Jauffret E, Jacquemier J, Spicuglia S, de The H, Viens P, Bertucci F, Birnbaum D, Chaffanet M (2014) Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS One 9(1):e81843. doi:10.1371/journal.pone.0081843
20. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel members (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.1093/annonc/mdt303
21. Varley KE, Mitra RD (2010) Bisulfite patch PCR enables multiplexed sequencing of promoter methylation across cancer samples. Genome Res 20(9):1279–1287. doi:10.1101/gr.101212.109
22. Flanagan JM, Cocciardi S, Waddell N, Johnstone CN, Marsh A, Henderson S, Simpson P, da Silva L, kConFab Investigators, Khanna K, Lakhani S, Boshoff C, Chenevix-Trench G (2010) DNA methylome of familial breast cancer identifies distinct profiles defined by mutation status. Am J Hum Genet 86(3):420–433. doi:10.1016/j.ajhg.2010.02.008
23. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6(2):65–70
24. Hollants S, Redeker EJ, Matthijs G (2012) Microfluidic amplification as a tool for massive parallel sequencing of the familial hypercholesterolemia genes. Clin Chem 58(4):717–724. doi:10.1373/clinchem.2011.173963
25. Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, Wang D, Guan Y, Ryner L, Koeppen H, Patel R, Hampton GM, Amler LC, Wang Y (2014) High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res 20(8):2080–2091. doi:10.1158/1078-0432.CCR-13-3114
26. Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lonning PE, Solvang H, Borresen-Dale AL, Tost J, Kristensen VN (2013) Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 13:456. doi:10.1186/1471-2407-13-456
27. Heyn H, Moran S, Hernando-Herraez I, Sayols S, Gomez A, Sandoval J, Monk D, Hata K, Marques-Bonet T, Wang L, Esteller M (2013) DNA methylation contributes to natural human variation. Genome Res 23(9):1363–1372. doi:10.1101/gr.154187.112
28. Xia YY, Ding YB, Liu XQ, Chen XM, Cheng SQ, Li LB, Ma MF, He JL (1846) Wang YX (2014) Racial/ethnic disparities in human DNA methylation. Biochim Biophys Acta 1:258–262. doi:10.1016/j.bbcan.2014.07.001
29. Ambrosone CB, Young AC, Sucheston LE, Wang D, Yan L, Liu S, Tang L, Hu Q, Freudenheim JL, Shields PG, Morrison CD, Demissie K, Higgins MJ (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5(1):237–248
30. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY (2009) Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 28(33):2969–2978. doi:10.1038/onc.2009.149
31. Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW (2009) DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 15(1):315–323. doi:10.1158/1078-0432.CCR-08-0166
32. Wojdacz TK, Windelov JA, Thestrup BB, Damsgaard TE, Overgaard J, Hansen L (2014) Identification and characterization of locus-specific methylation patterns within novel loci undergoing hypermethylation during breast cancer pathogenesis. Breast Cancer Res 16(1):R17. doi:10.1186/bcr3612
33. Twelves D, Nerurkar A, Osin P, Dexter T, Ward A, Gui GP, Isacke CM (2013) DNA promoter hypermethylation profiles in breast duct fluid. Breast Cancer Res Treat 139(2):341–350. doi:10.1007/s10549-013-2544-8
34. Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T (2013) Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat 142(2):365–380. doi:10.1007/s10549-013-2738-0
35. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Med 15(8):907–913. doi:10.1038/nm.2000
36. Li L, Lee KM, Han W, Choi JY, Lee JY, Kang GH, Park SK, Noh DY, Yoo KY, Kang D (2010) Estrogen and progesterone receptor status affect genome-wide DNA methylation profile in breast cancer. Hum Mol Genet 19(21):4273–4277. doi:10.1093/hmg/ddq351